BR112014025560A2 - anticorpos anti-pdgf-c - Google Patents
anticorpos anti-pdgf-cInfo
- Publication number
- BR112014025560A2 BR112014025560A2 BR112014025560A BR112014025560A BR112014025560A2 BR 112014025560 A2 BR112014025560 A2 BR 112014025560A2 BR 112014025560 A BR112014025560 A BR 112014025560A BR 112014025560 A BR112014025560 A BR 112014025560A BR 112014025560 A2 BR112014025560 A2 BR 112014025560A2
- Authority
- BR
- Brazil
- Prior art keywords
- pdgf
- antibodies
- inhibit
- pdgfr
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo patente de invenção: "anticorpos anti-pdgf-c". a presente invenção refere-se a anticorpos que se ligam ao antígeno pdgf-c e que têm a capacidade de inibir uma ligação de pdgf-c ao receptor pdgfr e de inibir a ativação de pdgfr através do pdgf-c. as aplicações de tais anticorpos também são descritas. as mesmas incluem o tratamento de câncer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261637372P | 2012-04-24 | 2012-04-24 | |
EP12165314 | 2012-04-24 | ||
US201261727231P | 2012-11-16 | 2012-11-16 | |
EP12192943 | 2012-11-16 | ||
PCT/EP2013/058513 WO2013160359A1 (en) | 2012-04-24 | 2013-04-24 | Anti-pdgf-c antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014025560A2 true BR112014025560A2 (pt) | 2017-07-04 |
Family
ID=49482233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014025560A BR112014025560A2 (pt) | 2012-04-24 | 2013-04-24 | anticorpos anti-pdgf-c |
Country Status (13)
Country | Link |
---|---|
US (1) | US9884910B2 (pt) |
EP (1) | EP2841454A1 (pt) |
JP (1) | JP2015515487A (pt) |
KR (1) | KR20150005631A (pt) |
CN (1) | CN104321343A (pt) |
AU (1) | AU2013254690B2 (pt) |
BR (1) | BR112014025560A2 (pt) |
CA (1) | CA2871528A1 (pt) |
IN (1) | IN2014DN09717A (pt) |
MX (1) | MX2014012843A (pt) |
NZ (2) | NZ724395A (pt) |
RU (1) | RU2014140116A (pt) |
WO (1) | WO2013160359A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015515487A (ja) | 2012-04-24 | 2015-05-28 | スロンボジェニックス エヌ.ブイ. | 抗pdgf−c抗体 |
JP7048505B2 (ja) * | 2015-11-10 | 2022-04-05 | パラクリン セラピューティクス エービー | Pdgf-cc阻害剤および抗エストロゲン剤によるer陰性乳癌の処置 |
MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
CN109843918B (zh) * | 2016-07-01 | 2023-08-25 | 旁分泌疗法公司 | 用于pdgf-cc抑制的方法和组合物 |
KR101943083B1 (ko) * | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
KR101943081B1 (ko) | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
BR112020011160A2 (pt) * | 2017-12-04 | 2020-11-17 | Laboratorios Salvat, S.A. | composição tópica oftálmica para o tratamento de doenças do segmento posterior do olho |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5304118A (en) | 1992-12-16 | 1994-04-19 | Trese Michael T | Method for performing a vitrectomy on an eye |
AU8296098A (en) | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
IL138488A0 (en) | 1998-03-17 | 2001-10-31 | Genentech Inc | Polypeptides homologous to vegf and bmp1 |
EP1123408A1 (en) | 1998-09-30 | 2001-08-16 | Ludwig Institute For Cancer Research | Platelet-derived growth factor c, dna coding therefor, and uses thereof |
US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
DE69939330D1 (de) * | 1998-12-07 | 2008-09-25 | Zymogenetics Inc | Wachstumsfaktor-homologe zvegf-3 |
AU8031700A (en) | 1999-10-21 | 2001-04-30 | Zymogenetics Inc. | Method of treating fibrosis |
EP1267627A1 (en) * | 2000-03-28 | 2003-01-02 | Ludwig Institute For Cancer Research | Non-human transgenic animals expressing platelet-derived growth factor c (pdgf-c) and uses thereof |
LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
CA2529798C (en) * | 2003-07-25 | 2014-09-16 | Zymogenetics, Inc. | Methods of treating hepatocellular carcinoma with zvegf3 antagonists |
US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
US8147828B2 (en) | 2006-04-17 | 2012-04-03 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
JP2015515487A (ja) | 2012-04-24 | 2015-05-28 | スロンボジェニックス エヌ.ブイ. | 抗pdgf−c抗体 |
-
2013
- 2013-04-24 JP JP2015507520A patent/JP2015515487A/ja active Pending
- 2013-04-24 CA CA2871528A patent/CA2871528A1/en not_active Abandoned
- 2013-04-24 KR KR1020147032459A patent/KR20150005631A/ko not_active Application Discontinuation
- 2013-04-24 BR BR112014025560A patent/BR112014025560A2/pt not_active IP Right Cessation
- 2013-04-24 RU RU2014140116A patent/RU2014140116A/ru not_active Application Discontinuation
- 2013-04-24 CN CN201380021028.7A patent/CN104321343A/zh active Pending
- 2013-04-24 NZ NZ724395A patent/NZ724395A/en unknown
- 2013-04-24 NZ NZ700274A patent/NZ700274A/en not_active IP Right Cessation
- 2013-04-24 AU AU2013254690A patent/AU2013254690B2/en not_active Expired - Fee Related
- 2013-04-24 US US14/404,052 patent/US9884910B2/en not_active Expired - Fee Related
- 2013-04-24 EP EP13722708.8A patent/EP2841454A1/en not_active Withdrawn
- 2013-04-24 MX MX2014012843A patent/MX2014012843A/es unknown
- 2013-04-24 WO PCT/EP2013/058513 patent/WO2013160359A1/en active Application Filing
-
2014
- 2014-11-18 IN IN9717DEN2014 patent/IN2014DN09717A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015515487A (ja) | 2015-05-28 |
NZ724395A (en) | 2018-03-23 |
EP2841454A1 (en) | 2015-03-04 |
US9884910B2 (en) | 2018-02-06 |
NZ700274A (en) | 2016-10-28 |
AU2013254690A1 (en) | 2014-11-06 |
RU2014140116A (ru) | 2016-06-10 |
KR20150005631A (ko) | 2015-01-14 |
CA2871528A1 (en) | 2013-10-31 |
CN104321343A (zh) | 2015-01-28 |
IN2014DN09717A (pt) | 2015-07-31 |
WO2013160359A1 (en) | 2013-10-31 |
US20150232546A1 (en) | 2015-08-20 |
MX2014012843A (es) | 2017-01-23 |
AU2013254690B2 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
BR112014025560A2 (pt) | anticorpos anti-pdgf-c | |
UA115402C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
BR112013010544A2 (pt) | moléculas de ligação ao egfr e imunoconjugados das mesmas | |
BR112013005699A2 (pt) | moléculas de ligação a 4-1bb | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
EA201390785A1 (ru) | Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения | |
WO2013123152A3 (en) | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER | |
WO2012078688A3 (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
SG184310A1 (en) | Antibodies that bind human cd27 and uses thereof | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201401204A1 (ru) | Антитела к il-23p19 | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201291065A1 (ru) | Антитела против vla-4 | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
MX2014013678A (es) | Agentes para neutralizacion de influenza. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |